Infection of rhesus monkeys with simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) is a key animal model for HIV-1 infection. Nonhuman primates (NHP) are complex, higher order species that require specialized infrastructure and experienced staff in a research setting. Core C (NHP Core) aims to support this IPCAVD program by providing all the expertise, infrastructure, reagents, personnel, animals, and logistics for the conduct of complex in vivo studies in rhesus monkeys. Core C will involve leadership from Beth Israel Deaconess Medical Center and Bioqual and is well positioned to meet program objectives. The goal of Core C is to provide leadership and technical expertise to ensure consistency and quality control in animal selection, execution of study protocols, experimental procedures, sample acquisition and distribution, and data collection and analysis. To accomplish this goal, we propose three Specific Aims:
Specific Aim 1. To support this IPCAVD program by selecting and providing rhesus monkeys, providing exceptional animal care, and conducting experimental vaccine studies Specific Aim 2. To provide facilities for the receipt, cataloging, processing, storage, and distribution of blood and tissue samples in compliance with Good Clinical Laboratory Practice Specific Aim 3. To obtain and to maintain all required regulatory approvals for the proposed studies

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI128751-04
Application #
10087863
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2018-02-01
Project End
2023-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
4
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank et al. (2018) Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243
Badamchi-Zadeh, Alexander; Moynihan, Kelly D; Larocca, Rafael A et al. (2018) Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol 201:2744-2752
Alter, Galit; Barouch, Dan (2018) Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe 24:25-33
Bricault, Christine A; Kovacs, James M; Badamchi-Zadeh, Alexander et al. (2018) Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol :
Whitney, James B; Lim, So-Yon; Osuna, Christa E et al. (2018) Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun 9:5429
Borducchi, Erica N; Liu, Jinyan; Nkolola, Joseph P et al. (2018) Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563:360-364
Barouch, Dan H (2018) A step forward for HIV vaccines. Lancet HIV 5:e338-e339